Letter from the Director
Dr. Robert Zivadinov, MD, PhD
Director, Buffalo Neuroimaging Analysis Center
February 4, 2010
My Friends,
I write to you today as our researchers are completing their analysis of the first of several studies on chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis (MS). The preliminary results are exciting scientifically and will generate a great deal of discussion among our colleagues and the wordwide press. The study itself continues into the second phase.
Good news! We will begin to offer CCSVI Diagnostic Venous Testing beginning this month. Patients may self-refer or be referred by their neurologist. We have also taken the first step towards treatment of CCSVI, a 6-month study titled, Controlled Randomized Endovascular Therapy (CRET). It will evaluate the safety and preliminary efficacy of therapeutic angioplasty. It is important to understand, however, that we cannot recommend endovascular treatment before we fully understand the safety of any approach we may propose. Thus, we intend to perform double-blind controlled trials using a treatment different from those used by either Prof. Zamboni or Prof. Michael Dake of Stanford. Many thanks to everyone who has been following our research, to those who participated in our first study and those interested in phase 2 of the CTEVD study.
Here is the link to the whole news letter with lots more information.
http://bnac.net/newsletter/BNAC_Newsletter_02-04-2010.pdf
How to Contact BNAC:
DISCLAIMER:
Receipt of this email means you are subscribed to the BNAC newsletter. It does not mean you are a part of any BNAC related study.
Please send only one inquiry to one of the email addresses listed below. Sending multiple emails hinders us in responding to those interested in these studies or testing.
If you have previously contacted ctevd@bnac.net or already filled out the CTEVD questionnaire, please be patient, we will contact you as soon as we can. You do not need to complete another questionnaire for this study. However, if you are interested in one of the other studies, you must email them directly and follow the application instructions. Please check the web site for updates regarding the CTEVD study.
If you would like more information on self referral testing packages please contact ccsvi.venoustesting@bnac.net.
If you would like more information on the CRET study please contact cret-ccsvi@bnac.net.
If you would like more information on the CTEVD study please contact ctevd@bnac.net.
Please Email, don't call!
Unfortunately, we have limited resources to answer phone calls and are overwhelmed with the response to our recent newsletter. Please contact us via email to the appropriate address listed below rather than via phone, and we will answer your emails as soon as possible. Thank you for your cooperation.
To get the most accurate and up to date information please visit our web site (www.bnac.net)
this is exciting...since my Ms isn't severe it makes me wonder if it is a vascular problem...
ReplyDeletedizziness, light headed, tingles, stiff joints, headaches, fatigue, all of which I have...plus whenever I start to exercise hard my left side tingles and feels weird...in my head it has to be something to do with blood flow.
I am glad you are pro-active about this. I haven't been. I am leaning on your information right now. Maybe when the baby is born I will take more aggressive steps.
This comment has been removed by a blog administrator.
ReplyDeleteThis comment has been removed by a blog administrator.
ReplyDeleteThis comment has been removed by a blog administrator.
ReplyDeleteStrategic Importance of Jugular Vein Dilatation Otherwise Known as ‘Liberation Therapy’
ReplyDeleteThe Combination Therapy includes neck vein dilatation based on the findings of Zamboni, et al. The vein dilatation or venoplasty therapy provides the appropriate drainage of the CNS that prevents a retrograde pressure exertion on the myelin sheath covering the CNS. Whatever triggers the autoimmune system to turn on in people predisposed to MS, this back-pressure needs to be resolved. In case after case, the typical symptoms of MS retreat in individuals where the veins are expanded and the flow pressures are equalized. Since keeping the jugular and azygous veins fully open is the key to reducing MS symptoms, it is of paramount importance to know what other post-procedure factors create enduring effect in the venous flow. For example, there is now good clinical and observational evidence to support the fact that stem cells (transplanted intravenously at the time of the venoplasty) reduce swelling, thrombin buildup, clotting and subsequent permanent intraluminal damage leading to scar tissue. As to what has already been established through clinical trials and subsequent therapeutic practice, it has been found that even in patients with severely malformed or abnormal jugular vein structure, the intravenous introduction of autologous stromal cells (MSCs) post-operatively has served to repair injury attributable to venoplastic damage and desquamation of the endothelial and subendothelial cells of the interior venous lumen (tunica intima). Peak velocity, time average velocity vein area, and flow quantification have been assessed by means of echo color Doppler at periodic intervals post-venoplasty. Significant hemodynamic improvement has been recorded at the level of the veins in the neck post-venoplasty. Moreover, this additional stem cell transplantation therapy has led to increased luminal diameter and improved patency rates demonstrating that the introduction of stem cells post-operatively significantly modifies the hemodynamics of the jugular veins more effectively than venoplasty alone.For more information please visit http://www.ccsviclinic.ca/?p=1194 or you may call the toll free number at 888-468-1554 or info@ccsviclinic.com